Atherosclerotic vascular disease in systemic lupus erythematosus

Journal of the National Medical Association

Volumn 94, Issue 9, 2002, Pages 813-819

  Liang, Matthew H ^a   Mandl, Lisa A ^a   Costenbader, Karen ^a   Ervin, Fox ^a   Karlson, Elizabeth ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Lupus; SLE; Vascular disease

Indexed keywords

AFRICAN AMERICAN; ARTERIOSCLEROSIS; ARTICLE; ETHNOLOGY; FEMALE; HUMAN; MALE; STATISTICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AFRICAN AMERICANS; ARTERIOSCLEROSIS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 0036726230     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-799.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-415.
3. Hosenpud JD, Montanaro A, Hart MV, et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984;77:286-292.
4. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus Erythematosus Arthritis Rheum. 1999;42:51-60.
5. Esdaile JM, Abrahamowicz M, Godzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
6. G. West SG. Neuropsychiatrie lupus. Rheum Dis Clin North Am. 1994;20:129-158.
7. Kaell AT, Shetty M, Lee BC, Lockshin MD. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients. Arch Neurol. 1986;43:273-276.
8. Futrell N, Millikan C. Frequency, etiology and prevention of stroke in patients with systemic lupus erythematosus. Stroke. 1989;20:583-591.
9. Liang MH, Partridge AJ, Daltroy LH, et al. Strategies for reducing excess morbidity and mortality in Blacks with systemic lupus erythematosus. Arthritis Rheum, 1991;34:1187-1196.
10. Walsh SJ, Algert C, Gregorio DI, Reisine ST, Rothfield NF. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheum. 1995;1663-1680.
11. Williams JE. Massing M, Rosamond WD, Sorlie PD, Tyroler HA. Racial disparities in CHD mortality from 1968-1992 in the state economic area surrounding the ARIC study communities. Ann Epidemiol. 1999;9:447-480.
12. Witzum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;793-795.
13. Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized LDL induce tissue factor expression in cultured human endothelial cells. Am J Pathol. 1991;601-607.
14. Brand K, Banka CL, Mackman N, et al. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocyte. Atheroscl Throm. 1994;790-797.
15. Lopes-Virella MF, Virrella GT. Atherosclerosis and autoimmunity. Clin Immunol Immunopathol. 1994;155-167.
16. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;27:27-33.
17. Kabakov AE, Tertov W, Saenko VA, Poverenny AM, Orekhov AN. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol. 1992;63:214-220.
18. Ames PRJ. Medical perspective: antiphospholipid antibodies, thrombosis and atherosclerosis in SLE: a unifying 'Membrane Stress Syndrome' hypothesis. Lupus. 1994;3:371-377.
19. Schwartz SM, Reidy MA, O'Brien ER. Assessment of factors important in atherosclerosis occlusion and restenosis. Thromb Hemost. 1995;74:541-551.
20. Asherson RA, Khamashta MA, Baguley E, et al. Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med. 1989;73:1103-1115.
21. Fyfe AI, Rosenthal A, Gotlieb AI. Immunosuppressive agents and endothelial repair. Prednisolone delays migration and cytoskeletal rearrangement in wounded porcine aortic monolayers. Arteriolscl Thromb Vas Biol. 1995;10:1166-1171.
22. Geiringer G, Hertzberg KM, Pind YKJ. Fibrinogen synthesis in serum-free hepatocyte cultures: stimulation by glucocorticosteroids. Proc Natl Acad Sci. 1978;75:5506-5510.
23. Flower RJ, Blackwell GJ. Antiinflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostoglandin generation. Nature. 1979;287:456-459.
24. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of c-reactive protein, fibrinogen, homocysteine, lipoprotein (a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485.
25. D'Agostino RB, Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group Validation of the Framingham Coronary Heart Disease Prediction Scores. Results of a multiple Ethnic Groups Investigation. JAMA. 2001;286:180-187.
26. Asher CR, Topol EJ, Moliterno DJ. Insights into the pathophysiology of atherosclerosis and progression of Black Americans with acute coronary syndromes. Am Heart J. 1999;138: 1073-1081.
27. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore). 1992;71:291-302.
28. Bruce IN, Gladman DD, Urowitz MB. Detection and modification of risk factors for coronary artery disease in patients with SLE. A quality improvement study. Clin Exp Rheumatol. 1998;16:435-440.
29. The Clinical Quality Improvement Network (CQIN) Investigators.Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol. 1995;76:570-573.
30. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. NEJM. 1998;339:1957-1963.
31. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998; 279:1458-1462.
32. Winkleby MA, Kraemer HC, Ahn DK, Varady AN. Ethnic and socioeconomic differences in cardiovascular disease risk factors. Findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA. 1998;280:356-362.
33. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J American College of Cardiology. 1997;29:139-146.
34. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S for the HERS Research Group. Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/ Progestin Replacement Study (HERS). JAMA. 1997;277:1281-1286.
35. Petri M, Roubenoff R, Dallai GE. et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
36. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96:254-259.
37. Metcalf PA, Sharrett AR, Folsom AR, et al. African American - White Differences in lipids, lipoproteins, and apolipoproteins, by educational attainment, among middle-aged adults: the atherosclerosis risk in communities study. Am J Epid. 1998;148: 750-760.
38. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation, 1986;74:758-765.
39. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp (a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
40. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990;36:20-23.
41. Sorrentino MJ, Vielrjauer C, Eisenbart JD, et al. Plasma lipoprotein (a) protein concentration and coronary artery disease in black patients compared with white patients. Am J Med. 1992;93:658-662.
42. Moliteino DJ, Jokinen EV, Miserez AR, et al. No association between plasma lipoprotein (a) concentrations and the presence or absence of coronary atherosclerosis in African Americans. Arthrioscler Thromb Vasc Biol 1995;15:850-855.
43. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp (a) levels to race and la apolipoprotein B. Atherosclerosis. 1985;5:265-272.